Aplagon Secures €7M to Advance Clinical Trials for Thrombo-Inflammatory Drug

Aplagon, a clinical-stage biopharmaceutical company, has successfully closed a €7 million financing round to accelerate the development of APAC, its first-in-class therapeutic for thrombo-inflammatory diseases. The funding was led by Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund, with participation from prominent Finnish investors, including the Jenny and Antti Wihuri Foundation, Innovestor, and the Gösta Serlachius Fine Arts Foundation. This investment will support the initiation of a Phase 2a clinical trial in Finland for patients with peripheral arterial occlusive disease (PAOD) and chronic limb-threatening ischemia (CLTI). Additionally, Aplagon is completing three ongoing clinical trials, including a Phase I study for arteriovenous fistula maturation failure and a PET-imaging trial for PAOD patients.

Aki Prihti, CEO of Aplagon, highlighted the significance of securing international venture capital support, emphasizing that the funding enables the company to advance its innovative heparin proteoglycan mimetic therapy. APAC, designed to target vascular injury sites, offers long-lasting antithrombotic and anti-inflammatory effects, positioning it as a potential breakthrough in vascular disease treatment. Johanna Asklin, General Partner at FSG and newly appointed Aplagon Board member, noted the growing need for novel solutions to address thrombo-inflammation in cardiovascular diseases. With this latest investment, Aplagon is poised to announce key clinical trial results in 2025 and 2026, bringing it closer to delivering life-changing therapies for patients worldwide.